Rathbones Group PLC Sells 150,000 Shares of Apyx Medical Co. (NASDAQ:APYX)

Rathbones Group PLC decreased its holdings in shares of Apyx Medical Co. (NASDAQ:APYX) by 59.7% during the fourth quarter, HoldingsChannel reports. The firm owned 101,334 shares of the company’s stock after selling 150,000 shares during the period. Rathbones Group PLC’s holdings in Apyx Medical were worth $160,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of APYX. Kingsview Wealth Management LLC boosted its stake in Apyx Medical by 8.7% in the 4th quarter. Kingsview Wealth Management LLC now owns 135,245 shares of the company’s stock worth $214,000 after purchasing an additional 10,800 shares in the last quarter. Commonwealth Equity Services LLC grew its holdings in shares of Apyx Medical by 3.0% during the fourth quarter. Commonwealth Equity Services LLC now owns 527,061 shares of the company’s stock worth $833,000 after buying an additional 15,500 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Apyx Medical by 7.5% during the fourth quarter. Geode Capital Management LLC now owns 352,809 shares of the company’s stock worth $558,000 after buying an additional 24,596 shares in the last quarter. Royce & Associates LP grew its holdings in shares of Apyx Medical by 1.3% in the fourth quarter. Royce & Associates LP now owns 2,615,369 shares of the company’s stock valued at $4,132,000 after purchasing an additional 32,879 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in Apyx Medical in the fourth quarter valued at about $134,000. Hedge funds and other institutional investors own 55.33% of the company’s stock.

Apyx Medical Trading Up 3.3 %

NASDAQ APYX opened at $0.90 on Thursday. The stock has a market capitalization of $34.01 million, a P/E ratio of -1.08 and a beta of 0.92. Apyx Medical Co. has a 12 month low of $0.76 and a 12 month high of $1.99. The company has a debt-to-equity ratio of 3.03, a current ratio of 5.46 and a quick ratio of 4.52. The firm’s 50-day moving average is $1.26 and its two-hundred day moving average is $1.37.

Apyx Medical (NASDAQ:APYX) last released its earnings results on Thursday, March 13th. The company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.01. The firm had revenue of $14.22 million for the quarter, compared to analyst estimates of $13.39 million. Apyx Medical had a negative net margin of 58.59% and a negative return on equity of 137.98%. On average, sell-side analysts anticipate that Apyx Medical Co. will post -0.68 earnings per share for the current year.

Apyx Medical Profile

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.